Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
NCT00492869 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 124
Last updated 2020-12-22
Summary
Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.
Conditions
- Kidney Transplantation
Interventions
- DRUG
-
AEB071
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-01-31
- Primary Completion
- 2008-05-31
Countries
- United States
- Belgium
- Canada
- Germany
- Spain
- Sweden
- United Kingdom
Study Locations
More Related Trials
-
Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program
NCT00956293 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients
NCT00229138 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients
NCT00170833 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
NCT00402168 ·Status: COMPLETED ·Phase: PHASE2
-
Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients
NCT00284934 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.
NCT00332839 ·Status: TERMINATED ·Phase: PHASE4
-
Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
NCT02118896 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids
NCT00239031 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation
NCT02123108 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
NCT00455013 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients
NCT00617604 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients
NCT01064791 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
NCT00251004 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
NCT01354301 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
NCT00154232 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
NCT00239876 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
NCT01265537 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT04877288 ·Status: RECRUITING ·Phase: PHASE3
-
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
NCT00263328 ·Status: COMPLETED ·Phase: PHASE2
-
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
NCT00658320 ·Status: COMPLETED ·Phase: PHASE3
-
Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation.
NCT00296309 ·Status: COMPLETED ·Phase: PHASE3
-
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
NCT01399593 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab for Prevention of Rejection After Renal Transplantation
NCT00565331 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
NCT00170859 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
NCT00035555 ·Status: COMPLETED ·Phase: PHASE2